Managing Crohn disease in children and adolescents: Focus on tumor necrosis factor antagonists

Pediatric Drugs

Volumn 10, Issue 1, 2008, Pages 31-38

  Saeed, Shehzad A ^a   Crandall, Wallace V ^b,c  

^a University of Alabama at Birmingham and Children's Hospital   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Adalimumab, therapeutic use; Adolescents; CDP 571, therapeutic use; Certolizumab pegol, therapeutic use; Children; Crohn's disease, treatment; Etanercept, therapeutic use; Infliximab, therapeutic use; Research and development; Semapimod, therapeutic use

Indexed keywords

ADALIMUMAB; ADRENALIN; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DIPHENHYDRAMINE; ETANERCEPT; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHYLPREDNISOLONE; ONERCEPT; PARACETAMOL; SEMAPIMOD; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ABSCESS; ADVERSE DRUG REACTION; BONE METABOLISM; CHILD GROWTH; CLINICAL TRIAL; CROHN DISEASE; CYTOPENIA; DIARRHEA; DRUG EFFECT; DRUG ELIMINATION; DRUG INFUSION REACTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; GROWTH DISORDER; HEART FAILURE; HEPATOSPLENIC T CELL LYMPHOMA; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; INFECTION; INFLAMMATION; INJECTION SITE REACTION; LISTERIOSIS; LIVER FAILURE; MENINGITIS; OPTIC NEURITIS; PARESTHESIA; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SEIZURE; SINGLE DRUG DOSE; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; CROHN DISEASE; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37549047191     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810010-00004     Document Type: Review

References (73)

1. Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three fold rise in Crohn's disease. Gut 1989; 30: 618-22
2. Langholz E, Munkholm P, Kraslinikoff PA, et al. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity and mortality in a regional cohort. Scand J Gastroenterol 1997; 32: 139-47
3. Kugathasan S, Judd RH, Hoffman RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a state-wide population based study. J Pediatr 2003; 143: 525-31
4. Bjornsson S, Johansson JH. Inflammatory bowel disease in Iceland, 1990-1994: a prospective, nationwide, epidemiological study. Eur J Gatroenterol Hepatol 2000; 12: 31-8
5. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999; 28: 445-58
6. Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescents: special considerations. Gastroenterol Clin North Am 2003; 32: 967-95
7. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999; 5: 285-94
8. Sands BE. Why do anti-tumor necrosis factor antibodies work in Crohn's disease? Rev Gastroenterol Disord 2004; 4 Suppl. 3: S10-7
9. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-57
10. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998; 188: 373-86
11. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-52
12. Pender SL, Fell JM, Chamow SM, et al. A p55 TNF receptor immunoadhesion prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998; 160: 4098-103
13. Bell D, Young JW, Banchereau J. Dendritic cells. Adv Immunol 1999; 72: 255-324
14. Mack DR, Young R, Kaufmann SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998; 132: 830-5
15. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990; 117: 809-14
16. Kirschner B. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813-21
17. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95: 3189-94
18. Hommes D, Baert F, van Assche G, et al. A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): 'top down' vs. 'step up' strategies [abstract no. W1017]. Digestive Diseases Week conference; 2005 May 14-19; Chicago (IL)
19. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn's disease. J Pediatr Gastroenterol Nutr 2005; 40: 220-2
20. Scallon BJ, Moore MA, Trinh H. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7: 251-9
21. Van den Brande JM, Braat H, VanDen Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85
22. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 14: 463-73
23. Baldassano R, Braeger CP, Escher JC, et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98: 833-8
24. Hyams JS, Markowitz J, Wylie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137: 192-6
25. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104-11
26. Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004; 10: 745-50
27. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1 year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1124-9
28. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factor (Remicade®) in severe pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2003; 36: 632-6
29. de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn's disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004; 39: 46-52
30. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003; 18: 425-31
31. Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-meracptopurine for the treatment of perianal Crohn's disease in children. J Clin Gastroenterol 2000; 30: 294-8
32. Kanof M, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95: 1523-7
33. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004; 36: 342-7
34. Wewer V, Riis L, Vind I, et al. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr 2006; 42: 40-5
35. Benkov KJ, Vorha P, Pittman NS, et al. Pathogenesis of immunological/inflammatory GI disease and IBD [abstract no. 86]. J Pediatr Gastroenterol Nutr 1996; 23: 363
36. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902
37. Steiner SJ, DiMeglio LA, Denne SC. Single dose of infliximab alters bone metabolism in pediatric Crohn's disease [poster]. 5th CCFA Annual Advances in Inflammatory Bowel Disease; 2006 Dec 1-3; Miami (FL)
38. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73
39. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 75-84
40. Mayer L, Young Y. Infusion reactions and their management. Gastroenterol Clinic N Am 2006, 866
41. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24
42. Rutgeerts P, Feagan BG, Lichtenstein G, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13
43. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251-8
44. Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor necrosis factor-α in the treatment of inflammatory bowel disease. Nat Clin Pract 2006; 3: 220-8
45. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I Trial. Gastroenterology 2006; 130: 323-33
46. Sandborn WJ, Hanauer SB, Lukas M, et al. Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of a blinded, placebo-controlled study [abstract no. 843]. Am J Gastroenterol 2005; 100 Suppl. S: S311
47. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response in patients with Crohn's disease: the CHARM Trial. Gastroenterol 2007; 132: 52-65
48. Sandborn WJ, Hanauer S, Loftus EV, et al. An open label study of the human anti-tnf monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 1984-9
49. Hinojosa J, Gomollon F, Nos P, et al. Four week results of adalimumab treatment in subjects with fistulizing Crohn's disease who have failed response or showed intolerance to infliximab [abstract no. 815]. Digestive Diseases Week; 2006 May 19-24; Los Angeles (CA)
50. Mian S, Baron H. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 2005; 41 (3): 357-9
51. Baldassano RN. Surpassing conventional therapies: the role of biologic therapy. J Pediatr Gastroenterol Nutr 2001; 33: S19-26
52. Kurtovic J, Segal I. Recent advances in biological therapy for inflammatory bowel disease. Trop Gastroenterol 2004; 25: 9-14
53. Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanized monoclonal antibody to tumor necrosis factor ?, for moderate to severe Crohn's disease: a randomized, double blind, placebo controlled trial. Gut 2004; 53: 1485-93
54. Mamula P, Cohen SA, Ferry GA, et al. CDP-571, a humanized anti tumor necrosis factor ? monoclonal antibody in pediatric Crohn's disease. Inflamm Bowel Dis 2004; 10: 723-30
55. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor ? production by stimulated human monocytes. J Exp Med 1991; 173: 699-703
56. Facchini S, Candusso M, Martelossi S, et al. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn's disease: preliminary results. J Pediatr Gastroenterol Nutr 2001; 32: 178-81
57. Martelossi S, Marchetti F, Lenhardt A, et al. Treatment with thalidomide in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: S282
58. Schreiber S, Rutgeerts P, Fedorak R, et al. A randomized placebo-controlled trial of certolizumab pegol (CDP 870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18
59. Schreiber S, Khaliq-Kareemi M, Lawrence I, et al. Certolizumab pegol, a humanized anti-TNF pegylated FAb' fragment, is safe, and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (PRECiSE). Gut 2005; 54 Suppl. VII: A82
60. Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): results of a randomized, open label, pilot study. Aliment Pharmacol Ther 2003; 17: 185-92
61. Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate to severe Crohn's disease: a randomized, double blind, placebo controlled trial. Clin Gastroenterol Hepatol 2006; 4: 888-93
62. D'Haens G, Swijsen C, Norman M, et al. Etanercept in the treatment of active refractory Crohn's disease: a single center pilot trial. Am J Gastroenterol 2001; 96: 2564-8
63. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94
64. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122: 7-14
65. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry. Clin Gastroenterol Hepatol 2006; 4: 621-30
66. Remicade® (infliximab) prescribing information. Malvern (PA): Centocor Inc., 2007
67. D' Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007; 56: 725-32
68. Surveillance, Epidemiology, and End Results Database (SEER) program. SEER incidence crude rates, 11 Registries, 1993-2001. Rockville (MD): National Cancer Institute
69. Humira® (adalimumab) prescribing information. Chicago (IL): Abbott Laboratories, 2007
70. Remicade® (infliximab) for IV injection prescribing information. Malvern (PA): Centocor Inc., 2007
71. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancy. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 296: 2275-85
72. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007; 13 (8): 1024-30
73. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-7